Our findings demonstrate the efficacious antitumor effects of BTZ in Myc-ATRT cells and orthopedic xenograft Myc-ATRT and strongly support the sensitivity to BTZ in SMARCB1-deficient cancers, particularly the Myc subgroup. Here, SMARCB1 is linked to cancer.